Type 1 Autoimmune Pancreatitis Can Transform into Chronic Pancreatitis: A Long-Term Follow-Up Study of 73 Japanese Patients
Table 2
Clinical features, laboratory tests, and pancreatic morphology at diagnosis.
Progression to CP ( = 16)
Nonprogression to CP ( = 57)
value
Clinical features
Median (range)
Observation period†
102 (37–165)
87 (36–230)
0.522
Age
66.5 (48–75)
65 (38–84)
0.989
Gender (M/F)
13/3
43/14
0.748
Alcohol (+/−)
6/10
29/28
0.405
PSL (+/−)
13/3
50/7
0.681
PSL maintenance therapy (+/−)
10/6
41/16
0.542
Relapse (+/−)
8/8
12/45
0.030*
Laboratory tests
IgG
2140 (1166–3861)
2227 (892–7236)
0.509
IgG4
421 (146–1845)
663 (4–2970)
0.267
C3
100 (52–122)
98 (29–218)
0.551
C4
21.8 (12.4–37.7)
21.1 (1.1–47.3)
0.495
sIL2-R
726 (132–1845)
892 (257–4695)
0.053
CIC
5 (1.9–13.9)
5.7 (1.4–40)
0.219
Pancreatic morphology at diagnosis
Pancreatic swelling
Head (+/−)
15/1
41/16
0.096
Body (+/−)
12/4
36/21
0.553
Tail (+/−)
10/6
37/20
1.000
Level 1/Level 2Φ
8/8
30/27
1.000
Ductal narrowing in MPD
Head (+/−)
13/3
44/13
1.000
Wirsung and Santorini (+/−)
11/5
34/23
0.573
Body (+/−)
3/13
37/20
0.001*
Tail (+/−)
12/4
42/15
1.000
Level 1 / Level 2Ψ
6/10
17/40
0.558
Ductal dilatation in MPD (+/−)
9/7
7/50
0.001*
Period from AIP diagnosis to the most recent observation (months). ΦSwelling was classified as level 1 (diffuse swelling) or level 2 (focal/segmental swelling) as defined by the International Consensus Diagnostic Criteria for Autoimmune Pancreatitis. ΨPancreatic duct narrowing was classified as level 1 (long (segmental/diffuse) or multiple strictures) or level 2 (focal narrowing) as defined by the International Consensus Diagnostic Criteria for Autoimmune Pancreatitis.
*
< 0.05. CP: chronic pancreatitis; PSL: prednisolone; sIL2-R: soluble interleukin 2 receptor; CIC: circulating immune complex; and MPD: main pancreatic duct.
